Objectif
Objectives:
% To collect information about purine and pyrimidine (PP) disorders in Europe and create a Network of people with special knowledge of these disorders and the experience required for their diagnosis.
To develop diagnostic services appropriate to each country through training programmes and increase awareness of these disorders among clinicians, service providers and patient support groups.
To develop a European database accessible through the Internet, which will include a table of defects, their prevalence, clinical and laboratory presentation and the location of diagnostic services.
To coordinate and advance basic research into the pathophysiology of PP-disorders by promoting exchange and training of talented young European researchers and bring together the critical mass of state of the art equipment and knowledge in the form of experienced personnel.
To establish a bank of genetically deficient cells to minimise research involving animal experimentation and promote collaboration with European industry to develop screening tests for the detection of PP-disorders and new drugs for their treatment.
To apply the knowledge derived from these genetic disorders to research devoted to understanding and treating more common conditions e.g. cancer, leukaemia, rheumatoid arthritis, heart disease.
The aim of this project is to enhance understanding of the disease mechanisms involved in inborn errors of purine and pyrimidine (PP) metabolism, improve European diagnostic structures and develop therapeutic strategies to treat these disorders. This is vital not only because the diseases themselves can jeopardise children's lives, but also because of the importance of the study of these disorders in understanding energy and nucleotide metabolism in humans. This metabolism serves many important functions, including the synthesis of the building blocks of DNA. Genetic defects involving single enzymes in these pathways may present as anaemia, gout, immunodeficiency, kidney stones, renal failure, or severe neurological deficits in children and adults, sometimes as life-threatening reactions to analogue therapy. This range means there is noone clinical speciality to give support. They are recently recognised and little known in Europe. Few diagnostic services exist, nine countries apparently having no such service. Early death, institutionalisation for life, or progression to dialysis and transplantation is frequent. Treatment where possible is life-long. They are thus 'orphan diseases', frequently misdiagnosed or undiagnosed, tragic to the family and costly to European health services.
Their apparent rarity means that they do not attract research funding locally and no country alone can provide the case mix or resources required improving treatment. Diagnosis requires specialist centres aware of potential pitfalls, which can mask correct diagnosis, such as blood transfusion or drugs. Importantly, knowledge derived from these 'experiments of nature' helps delineate normal and is now being applied to understanding and treating more prevalent conditions.
This proposal, forms part of a longer-term plan supported by the European Society for the Study of Purine and Pyrimidine Metabolism (ESSPPM) to establish a network to advance diagnosis and promote collaborative research into PP and allied disorders with its headquarters at the UMDS Guy's Hospital, London, GB.
The major aims of this project are to: a) collect information about PP disorders in Europe and create a network of people with special knowledge of these rare disorders and the experience required for their correct diagnosis; b) develop diagnostic services appropriate to each country through training programmes and increase awareness by making information available to clinicians, service providers and patient support groups; c) develop a European database accessible through the Internet, which will include a table of defects, their prevalence, clinical and laboratory presentation and the location of diagnostic services; d) coordinate and advance basic research into the pathophysiology of PP disorders by promoting exchange and training of talented young European researchers and bringing together the critical mass of state of the art equipment and knowledge in the form of experienced personnel; e)establish a bank of genetically deficient cells to minimise research involving animal experimentation and collaborate with European industry to develop screening tests for the detection of PP disorders and new drugs for their treatment. The benefits would be: f)improved quality of life for all patients and families and cost-effectiveness through avoidance of unnecessary tests, delay or mistakes in diagnosis, lack of awareness, or inadequate reference data; g)advancement of knowledge and European research capability through training and exchange; h) backup for European industry with unique expertise, research facilities and patient population. 01 01
Champ scientifique (EuroSciVoc)
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.
- sciences naturelles informatique et science de l'information internet
- sciences médicales et de la santé médecine clinique rhumatologie
- sciences médicales et de la santé médecine fondamentale physiologie pathophysiologie
- sciences médicales et de la santé médecine clinique transplantation
- sciences médicales et de la santé médecine clinique oncologie leucémie
Vous devez vous identifier ou vous inscrire pour utiliser cette fonction
Programme(s)
Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.
Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.
Thème(s)
Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.
Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.
Appel à propositions
Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.
Données non disponibles
Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.
Régime de financement
Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.
Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.
Coordinateur
SE1 9RT London
Royaume-Uni
Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.